Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dawn Svoronos | F | 70 | 11 years | |
| Paul Lévesque | M | 60 | 4 years | |
| Dale MacCandlish-Weil | F | 68 | 7 years | |
| Jocelyn Lafond | M | 56 | 17 years | |
| Marie-Noël Colussi | F | 55 | 27 years | |
| Philippe Dubuc | M | 57 | 8 years | |
| Christian Marsolais | M | 61 | 17 years | |
| Jean-François Leduc | M | - |
University of Sherbrooke
| 40 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Philippe Calais | M | 65 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Robert A. Dubé | M | - |
University of Sherbrooke
| 8 years |
| David D. Lilley | M | 66 | - | |
| Sheila Frame | F | 62 | 2 years | |
| Gérald A. Lacoste | M | 80 | 18 years | |
| Bernard Reculeau | M | 72 | - | |
| John-Michel Huss | M | 59 | 2 years | |
| Gary Littlejohn | M | 68 | 5 years | |
| Martine Ortega | F | - | - | |
| Martin Delage | M | - |
University of Sherbrooke
| 6 years |
| Yves Baribeault | M | - |
University of Sherbrooke
| 8 years |
| Gilles Cloutier | M | 79 | 12 years | |
| Yves Rosconi | M | - | 6 years | |
| Jean-Denis Talon | M | 83 | 18 years | |
| Paul Pommier | M | 81 | 24 years | |
| André de Villers | M | - | 11 years | |
| Stephen G. Sudovar | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Robert G. Goyer | M | - | - | |
| André Lachance | M | - |
University of Sherbrooke
| 4 years |
| Richard Dussault | M | - |
University of Sherbrooke
| 4 years |
| François Desjardins | M | 61 |
University of Sherbrooke
| 3 years |
| Andrea Gilpin | M | - | - | |
| Krishna Peri | M | - | - | |
| Pierre Perazzelli | M | 72 | - | |
| Leah Gibson | F | - | 1 years | |
| Yvan Ouellet | M | - |
University of Sherbrooke
| 4 years |
| P. Mario Charpentier | M | - |
University of Sherbrooke
| 4 years |
| Normand Bouchard | M | - |
University of Sherbrooke
| 4 years |
| Jocelyn Trottier | M | - |
University of Sherbrooke
| 4 years |
| Joseph J. Krivulka | M | 73 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Michel Houde | M | - |
University of Sherbrooke
| 4 years |
| Alain Fontaine | M | 69 |
University of Sherbrooke
| 4 years |
| Diane Fontaine | F | 60 |
University of Sherbrooke
| 4 years |
| Jovan Antunovic | M | - | 2 years | |
| Denis Boucher | M | 58 | 3 years | |
| Mike Cegelski | M | - |
University of Sherbrooke
| 3 years |
| Bernard Guy | M | 59 |
University of Sherbrooke
| 4 years |
| Ghyslain Rivard | M | 64 |
University of Sherbrooke
| 4 years |
| Luc Paquet | M | 59 |
University of Sherbrooke
| 4 years |
| Lyne Fortin | F | 64 | 5 years | |
| Serge Chiasson | M | - |
University of Sherbrooke
| 2 years |
| Jean Charest | M | 66 |
University of Sherbrooke
| 3 years |
| Daniel Courchesne | M | - |
University of Sherbrooke
| 4 years |
| Pierre Bonin | M | 60 |
University of Sherbrooke
| 4 years |
| Paul Mathurin | M | 70 |
University of Sherbrooke
| 2 years |
| Julie Mac Allister | F | - | 1 years | |
| Alain Brunelle | M | - |
University of Sherbrooke
| 4 years |
| Jean-Paul St-Pierre | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 3 years |
| Soraya Allas | M | - | 7 years | |
| Luc Robert | M | 67 |
University of Sherbrooke
| 4 years |
| René Bousquet | M | - |
University of Sherbrooke
| 5 years |
| Guylaine Lehoux | F | - |
University of Sherbrooke
| 4 years |
| Louis Philippe Chasles | M | - |
University of Sherbrooke
| 3 years |
| Serve Régnier | M | 69 |
University of Sherbrooke
| 4 years |
| Charles Spector | M | 65 |
University of Sherbrooke
| 3 years |
| Robert Hall | M | 67 |
University of Sherbrooke
| 3 years |
| Max E. Link | M | 84 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
| André Bolduc | M | - |
University of Sherbrooke
| 4 years |
| Roch Leblanc | M | 67 |
University of Sherbrooke
| 4 years |
| Carl Simard | M | - |
University of Sherbrooke
| 2 years |
| Bernard Coupal | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 8 years |
| Monique Lefebvre | F | 77 | 2 years | |
| Marc Duchesne | M | - |
University of Sherbrooke
| 4 years |
| Chandrakant Panchal | M | 74 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 2 years |
| Pierre Rougeau | M | 66 |
University of Sherbrooke
| 1 years |
| Luc Houle | M | 67 |
University of Sherbrooke
| 4 years |
| Jacques Chartrand | M | - |
University of Sherbrooke
| 4 years |
| Pierre Bernard | M | - |
University of Sherbrooke
| 4 years |
| Hans J. Mäder | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
| Frédéric Porte | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | - |
| Daniel Bourbeau | M | - |
University of Sherbrooke
| 3 years |
| Pierre A. Caudrelier | M | - | - | |
| Gilles Pepin | M | - |
University of Sherbrooke
| 4 years |
| Nasrat Hakim | M | 63 | 7 years | |
| Eric Reiher | M | - |
University of Sherbrooke
| 4 years |
| Jean-Guy Talbot | M | - |
University of Sherbrooke
| 3 years |
| Jinzi Wu | M | 61 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 4 years |
| André Lepage | M | - |
University of Sherbrooke
| 3 years |
| M. Jacques Joly | M | - |
University of Sherbrooke
| 4 years |
| Paul-Henry Schmelck | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 3 years |
| José Boisjoli | M | 66 |
University of Sherbrooke
| 4 years |
| François Lombard | M | 76 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 3 years |
| Gérard Geoffrion | M | 72 |
University of Sherbrooke
| 2 years |
| Joe DiMassimo | M | - |
University of Sherbrooke
| 2 years |
| Alain Bellemare | M | 63 |
University of Sherbrooke
| 4 years |
| Monique Létourneau | F | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 8 years |
| Pierre Fréchette | M | - |
University of Sherbrooke
| 4 years |
| André Michel | M | - |
University of Sherbrooke
| 10 years |
| Michael Quigley | M | - |
University of Sherbrooke
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 98 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Luc Tanguay
- Personal Network
